Subjects the adjunctive hemodynamic indicator with decision point -- a device that monitors medical conditions relating to blood flow -- to special regulatory controls, including mandating a risk assessment and the reporting of clinical data proving the devices's efficacy.
Classifies the adjunctive hemodynamic indicator with decision point -- a device that monitors medical conditions relating to blood flow -- into the Food & Drug Administration's class II, requiring special controls. That set of controls:
Requires a full description of the technical parameters of the device's software and sensors.
Requires a risk assessment for the device.
Requires mechanisms designed to mitigate the impact of user error or failure of any subsystem components (signal detection and analysis, data display, and storage) on the accuracy of the device's output.
Requires statistical documentation, based on robust clinical data, of the device's efficacy. The accuracy of the device's algorithm must be tested using an independent dataset.
Requires a usability assessment to demonstrate that the risk of misinterpretation of the status indicator is appropriately mitigated.
Requires detailed product labeling.
Key facts
🏛️ This document has been enacted by the U.S. Food and Drug Administration.
For authoritative text and metadata, visit the official source.
🎯 This document primarily applies to the private sector, rather than the government.
📜 This document's name is 21 CFR § 864.3750 ("Adjunctive hemodynamic indicator with decision point").
Themes
AI risks, applications, governance strategies, and other themes addressed in AGORA documents.
This tag applies to documents that address whether humans can understand (a) the mechanisms underlying an AI system’s operation and/or (b) the meaning of the systems’ output in the context of use.
This tag applies to documents that address the ability of an AI system to perform as required, without failure, under the conditions of expected use and over a given period of time, including the entire lifetime of the system.
This tag applies to documents that require, encourage, etc. the disclosure of information about AI systems by their users, developers, vendors, or others directly involved with the systems to third parties, including but not limited to the general public.
This tag applies to documents that require, encourage, etc. the systematic evaluation of AI systems, or of broader systems or processes into which AI is directly integrated.
This tag applies to documents that discuss evaluations that assess whether deployed AI systems meet the expectations specified or claimed prior to deployment.
This tag applies to documents that require or incentivize AI systems to incorporate specific features or achieve (or not achieve) specified results in operation, or to be used or not to be used in specified ways or for specific purposes. Requirements may be defined objectively (e.g., systems must score above a certain level on an established benchmark, systems must incorporate a certain technical feature) or subjectively (e.g., systems must not demonstrate undue bias).
This is an unofficial copy. The document has been
archived and reformatted in plaintext for AGORA. Footnotes, tables, and
similar material may be omitted. For the official text, visit the original source.
§ 870.2220 Adjunctive hemodynamic indicator with decision point.
(a) Identification.
An adjunctive hemodynamic indicator with decision point is a device that identifies and monitors hemodynamic condition(s) of interest and provides notifications at a clinically meaningful decision point. This device is intended to be used adjunctively along with other monitoring and patient information.
Identifies and monitors hemodynamic conditions, providing notifications at a clinically meaningful decision point.
Identifies and monitors hemodynamic conditions, providing notifications at a clinically meaningful decision point.
(b) Classification.
Class II (special controls). The special controls for this device are:
(1) Software description, verification, and validation based on comprehensive hazard analysis and risk assessment must be provided, including:
(i) Full characterization of technical parameters of the software, including algorithm(s);
(ii) Description of the expected impact of all applicable sensor acquisition hardware characteristics on performance and any associated hardware specifications;
(iii) Specification of acceptable incoming sensor data quality control measures;
(iv) Mitigation of impact of user error or failure of any subsystem components (signal detection and analysis, data display, and storage) on output accuracy; and
(v) The sensitivity, specificity, positive predictive value, and negative predictive value in both percentage and number form for clinically meaningful pre-specified time windows consistent with the device output.
(2) Scientific justification for the validity of the hemodynamic indicator algorithm(s) must be provided. Verification of algorithm calculations and validation testing of the algorithm must use an independent data set.
(3) Usability assessment must be provided to demonstrate that risk of misinterpretation of the status indicator is appropriately mitigated.
Requires software validation, algorithm verification, usability assessment, and scientific justification for hemodynamic indicators in AI devices.
Requires software validation, algorithm verification, usability assessment, and scientific justification for hemodynamic indicators in AI devices.
(4) Clinical data must support the intended use and include the following:
(i) The assessment must include a summary of the clinical data used, including source, patient demographics, and any techniques used for annotating and separating the data;
(ii) Output measure(s) must be compared to an acceptable reference method to demonstrate that the output represents the measure(s) that the device provides in an accurate and reproducible manner;
(iii) The data set must be representative of the intended use population for the device. Any selection criteria or limitations of the samples must be fully described and justified;
(iv) Where continuous measurement variables are displayed, agreement of the output with the reference measure(s)
must be assessed across the full measurement range; and
(v) Data must be provided within the clinical validation study or using equivalent datasets to demonstrate the consistency of the output and be representative of the range of data sources and data quality likely to be encountered in the intended use population and relevant use conditions in the intended use environment.
Requires clinical data to support intended use, including assessment, comparison, representation, agreement, and consistency.
Requires clinical data to support intended use, including assessment, comparison, representation, agreement, and consistency.
(5) Labeling must include the following:
(i) The type of sensor data used, including specification of compatible sensors for data acquisition, and a clear description of what the device measures and outputs to the user;
(ii) Warnings identifying factors that may impact output results;
(iii) Guidance for interpretation of the outputs, including warning(s) specifying adjunctive use of the measurements;
(iv) Key assumptions made in the calculation and determination of measurements; and
(v) A summary of the clinical validation data, including details of the patient population studied (e.g., age, gender, race/ethnicity), clinical study protocols, and device performance with confidence intervals for all intended use populations.
Mandates labeling to specify sensor data, warnings, output interpretation, assumptions, and clinical validation summary.
Mandates labeling to specify sensor data, warnings, output interpretation, assumptions, and clinical validation summary.